NSG 6005 WEEK 1 REVISION HANDBOOK
2026 EVIDENCE BASED PRACTICE AND
CLINICAL GUIDELINES
◉ Inadequate vitamin D intake can contribute to the development of
osteoporosis by:
A. Increasing calcitonin production
B. Increasing calcium absorption from the intestine
C. Altering calcium metabolism
D. Stimulating bone formation
Answer: B. Increasing calcium absorption from the intestine
◉ The drug recommended as primary prevention of osteoporosis in
men over seventy years is:
A. Alendronate (Fosamax)
B. Ibandronate (Boniva)
C. Calcium carbonate
D. Raloxifene (Evista)
Answer: A. Alendronate (Fosamax)
,◉ When starting a patient with hypothyroidism on thyroid
replacement hormones, patient education would include the
following:
A. He or she should feel symptomatic improvement in one to two
weeks.
B. Drug-related adverse effects such as lethargy and dry skin may
occur.
C. It may take four to eight weeks to get to euthyroid
symptomatically and by lab testing.
D. Due to the short half-life of levothyroxine, its doses should not be
missed.
Answer: C. It may take four to eight weeks to get to euthyroid
symptomatically and by lab testing.
◉ The drug recommended as primary prevention of osteoporosis in
women over seventy years old is:
A. Alendronate (Fosamax)
B. Ibandronate (Boniva)
C. Calcium carbonate
D. Raloxifene (Evista)
Answer: A. Alendronate (Fosamax)
, ◉ Goals of treatment when treating hypothyroidism with thyroid
replacement include:
A. Normal TSH and free T4 levels
B. Resolution of fatigue
C. Weight loss to baseline
D. All of the above
Answer: D. All of the above
◉ Intranasal calcitonin is used in the treatment of osteoporosis. For
which patient is Calcitonin therapy appropriate?
A. Thin, Caucasian perimenopausal women
B. Men over the age of sixty-five years with osteoporosis
C. Women over the age of sixty-five years with osteopenia
D. Women over the age of sixty-five years with severe osteoporosis
Answer: D. Women over the age of sixty-five years with severe
osteoporosis
◉ Bisphosphonates treat or prevent osteoporosis by:
A. Inhibiting osteoclastic activity
2026 EVIDENCE BASED PRACTICE AND
CLINICAL GUIDELINES
◉ Inadequate vitamin D intake can contribute to the development of
osteoporosis by:
A. Increasing calcitonin production
B. Increasing calcium absorption from the intestine
C. Altering calcium metabolism
D. Stimulating bone formation
Answer: B. Increasing calcium absorption from the intestine
◉ The drug recommended as primary prevention of osteoporosis in
men over seventy years is:
A. Alendronate (Fosamax)
B. Ibandronate (Boniva)
C. Calcium carbonate
D. Raloxifene (Evista)
Answer: A. Alendronate (Fosamax)
,◉ When starting a patient with hypothyroidism on thyroid
replacement hormones, patient education would include the
following:
A. He or she should feel symptomatic improvement in one to two
weeks.
B. Drug-related adverse effects such as lethargy and dry skin may
occur.
C. It may take four to eight weeks to get to euthyroid
symptomatically and by lab testing.
D. Due to the short half-life of levothyroxine, its doses should not be
missed.
Answer: C. It may take four to eight weeks to get to euthyroid
symptomatically and by lab testing.
◉ The drug recommended as primary prevention of osteoporosis in
women over seventy years old is:
A. Alendronate (Fosamax)
B. Ibandronate (Boniva)
C. Calcium carbonate
D. Raloxifene (Evista)
Answer: A. Alendronate (Fosamax)
, ◉ Goals of treatment when treating hypothyroidism with thyroid
replacement include:
A. Normal TSH and free T4 levels
B. Resolution of fatigue
C. Weight loss to baseline
D. All of the above
Answer: D. All of the above
◉ Intranasal calcitonin is used in the treatment of osteoporosis. For
which patient is Calcitonin therapy appropriate?
A. Thin, Caucasian perimenopausal women
B. Men over the age of sixty-five years with osteoporosis
C. Women over the age of sixty-five years with osteopenia
D. Women over the age of sixty-five years with severe osteoporosis
Answer: D. Women over the age of sixty-five years with severe
osteoporosis
◉ Bisphosphonates treat or prevent osteoporosis by:
A. Inhibiting osteoclastic activity
